Modeling of C/EBPalpha mutant acute myeloid leukemia reveals a common expression signature of committed myeloid leukemia-initiating cells
- PMID: 18394553
- DOI: 10.1016/j.ccr.2008.02.008
Modeling of C/EBPalpha mutant acute myeloid leukemia reveals a common expression signature of committed myeloid leukemia-initiating cells
Abstract
Mutations in the CEBPA gene are present in 7%-10% of human patients with acute myeloid leukemia (AML). However, no genetic models exist that demonstrate their etiological relevance. To mimic the most common mutations affecting CEBPA-that is, those leading to loss of the 42 kDa C/EBPalpha isoform (p42) while retaining the 30kDa isoform (p30)-we modified the mouse Cebpa locus to express only p30. p30 supported the formation of granulocyte-macrophage progenitors. However, p42 was required for control of myeloid progenitor proliferation, and p42-deficient mice developed AML with complete penetrance. p42-deficient leukemia could be transferred by a Mac1+c-Kit+ population that gave rise only to myeloid cells in recipient mice. Expression profiling of this population against normal Mac1+c-Kit+ progenitors revealed a signature shared with MLL-AF9-transformed AML.
Comment in
-
C/EBPalpha in leukemogenesis: a matter of being in the right place with the right signals.Cancer Cell. 2008 Apr;13(4):289-91. doi: 10.1016/j.ccr.2008.03.009. Cancer Cell. 2008. PMID: 18394549
Similar articles
-
C/EBPalpha in leukemogenesis: a matter of being in the right place with the right signals.Cancer Cell. 2008 Apr;13(4):289-91. doi: 10.1016/j.ccr.2008.03.009. Cancer Cell. 2008. PMID: 18394549
-
C/EBPα-p30 confers AML cell susceptibility to the terminal unfolded protein response and resistance to Venetoclax by activating DDIT3 transcription.J Exp Clin Cancer Res. 2024 Mar 13;43(1):79. doi: 10.1186/s13046-024-02975-3. J Exp Clin Cancer Res. 2024. PMID: 38475919 Free PMC article.
-
C/EBPα-p30 protein induces expression of the oncogenic long non-coding RNA UCA1 in acute myeloid leukemia.Oncotarget. 2015 Jul 30;6(21):18534-44. doi: 10.18632/oncotarget.4069. Oncotarget. 2015. PMID: 26053097 Free PMC article.
-
Molecular mechanisms underlying deregulation of C/EBPalpha in acute myeloid leukemia.Int J Hematol. 2010 May;91(4):557-68. doi: 10.1007/s12185-010-0573-1. Epub 2010 Apr 27. Int J Hematol. 2010. PMID: 20422469 Review.
-
C/EBPalpha and the pathophysiology of acute myeloid leukemia.Curr Opin Hematol. 2006 Jan;13(1):7-14. doi: 10.1097/01.moh.0000190110.08156.96. Curr Opin Hematol. 2006. PMID: 16319681 Review.
Cited by
-
Acute myeloid leukemia stem cells and CD33-targeted immunotherapy.Blood. 2012 Jun 28;119(26):6198-208. doi: 10.1182/blood-2011-11-325050. Epub 2012 Jan 27. Blood. 2012. PMID: 22286199 Free PMC article. Review.
-
Repression of transcriptional activity of C/EBPalpha by E2F-dimerization partner complexes.Mol Cell Biol. 2010 May;30(9):2293-304. doi: 10.1128/MCB.01619-09. Epub 2010 Feb 22. Mol Cell Biol. 2010. PMID: 20176812 Free PMC article.
-
Molecular mechanisms for stemness maintenance of acute myeloid leukemia stem cells.Blood Sci. 2019 Sep 17;1(1):77-83. doi: 10.1097/BS9.0000000000000020. eCollection 2019 Aug. Blood Sci. 2019. PMID: 35402786 Free PMC article.
-
A computational evaluation of over-representation of regulatory motifs in the promoter regions of differentially expressed genes.BMC Bioinformatics. 2010 May 20;11:267. doi: 10.1186/1471-2105-11-267. BMC Bioinformatics. 2010. PMID: 20487530 Free PMC article.
-
A C/ebpα isoform specific differentiation program in immortalized myelocytes.Leukemia. 2023 Sep;37(9):1850-1859. doi: 10.1038/s41375-023-01989-8. Epub 2023 Aug 2. Leukemia. 2023. PMID: 37532789 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Molecular Biology Databases